Evidence map›Paper›PMID 30260753›Full record

ArticleJournal of global oncology2018

Treating EGFR-Mutated Oncogene-Addicted Advanced Non-Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities.

Elena Fountzilas, Sofia Levva, Giannis Mountzios, Genovefa Polychronidou, Nikos Maniadakis, Vassiliki Kotoula, George Fountzilas

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of global oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Elena FountzilasElena Fountzilas, MD Anderson Cancer Center, The University of Texas, Houston, TX; Sofia Levva and Genovefa Polychronidou, Papageorgiou Hospital; Sofia Levva, Genovefa Polychronidou, and Vassiliki Kotoula, School of Health Sciences, Aristotle University of Thessaloniki; Vassiliki Kotoula and George Fountzilas, Hellenic Foundation for Cancer Research; George Fountzilas, Aristotle University of Thessaloniki, Thessaloniki; Giannis Mountzios, Henry Dunant Hospital Center; and Nikos Maniadakis, National School οf Public Health, Athens, Greece.
Sofia LevvaElena Fountzilas, MD Anderson Cancer Center, The University of Texas, Houston, TX; Sofia Levva and Genovefa Polychronidou, Papageorgiou Hospital; Sofia Levva, Genovefa Polychronidou, and Vassiliki Kotoula, School of Health Sciences, Aristotle University of Thessaloniki; Vassiliki Kotoula and George Fountzilas, Hellenic Foundation for Cancer Research; George Fountzilas, Aristotle University of Thessaloniki, Thessaloniki; Giannis Mountzios, Henry Dunant Hospital Center; and Nikos Maniadakis, National School οf Public Health, Athens, Greece.
Giannis MountziosElena Fountzilas, MD Anderson Cancer Center, The University of Texas, Houston, TX; Sofia Levva and Genovefa Polychronidou, Papageorgiou Hospital; Sofia Levva, Genovefa Polychronidou, and Vassiliki Kotoula, School of Health Sciences, Aristotle University of Thessaloniki; Vassiliki Kotoula and George Fountzilas, Hellenic Foundation for Cancer Research; George Fountzilas, Aristotle University of Thessaloniki, Thessaloniki; Giannis Mountzios, Henry Dunant Hospital Center; and Nikos Maniadakis, National School οf Public Health, Athens, Greece.
Genovefa PolychronidouElena Fountzilas, MD Anderson Cancer Center, The University of Texas, Houston, TX; Sofia Levva and Genovefa Polychronidou, Papageorgiou Hospital; Sofia Levva, Genovefa Polychronidou, and Vassiliki Kotoula, School of Health Sciences, Aristotle University of Thessaloniki; Vassiliki Kotoula and George Fountzilas, Hellenic Foundation for Cancer Research; George Fountzilas, Aristotle University of Thessaloniki, Thessaloniki; Giannis Mountzios, Henry Dunant Hospital Center; and Nikos Maniadakis, National School οf Public Health, Athens, Greece.
Nikos ManiadakisElena Fountzilas, MD Anderson Cancer Center, The University of Texas, Houston, TX; Sofia Levva and Genovefa Polychronidou, Papageorgiou Hospital; Sofia Levva, Genovefa Polychronidou, and Vassiliki Kotoula, School of Health Sciences, Aristotle University of Thessaloniki; Vassiliki Kotoula and George Fountzilas, Hellenic Foundation for Cancer Research; George Fountzilas, Aristotle University of Thessaloniki, Thessaloniki; Giannis Mountzios, Henry Dunant Hospital Center; and Nikos Maniadakis, National School οf Public Health, Athens, Greece.
Vassiliki KotoulaElena Fountzilas, MD Anderson Cancer Center, The University of Texas, Houston, TX; Sofia Levva and Genovefa Polychronidou, Papageorgiou Hospital; Sofia Levva, Genovefa Polychronidou, and Vassiliki Kotoula, School of Health Sciences, Aristotle University of Thessaloniki; Vassiliki Kotoula and George Fountzilas, Hellenic Foundation for Cancer Research; George Fountzilas, Aristotle University of Thessaloniki, Thessaloniki; Giannis Mountzios, Henry Dunant Hospital Center; and Nikos Maniadakis, National School οf Public Health, Athens, Greece.
George FountzilasElena Fountzilas, MD Anderson Cancer Center, The University of Texas, Houston, TX; Sofia Levva and Genovefa Polychronidou, Papageorgiou Hospital; Sofia Levva, Genovefa Polychronidou, and Vassiliki Kotoula, School of Health Sciences, Aristotle University of Thessaloniki; Vassiliki Kotoula and George Fountzilas, Hellenic Foundation for Cancer Research; George Fountzilas, Aristotle University of Thessaloniki, Thessaloniki; Giannis Mountzios, Henry Dunant Hospital Center; and Nikos Maniadakis, National School οf Public Health, Athens, Greece.
Regional Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBecause of the profound financial crisis that commenced in Greece in 2010, severe cuts in health care spending and other restriction measures led to significant delays in the reimbursement of novel antineoplastic agents. In 2011, the Hellenic Society of Medical Oncology initiated a program of early access to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of patients with advanced, EGFR-mutant non-small-cell lung cancer (NSCLC). We evaluated treatment patterns and clinical outcomes in patients with EGFR-mutant or wild-type disease treated at a large center in Greece throughout the period of financial crisis. PATIENTS AND

methodsFrom 2011 through 2015, 252 patients with newly diagnosed advanced NSCLC were treated at the Department of Medical Oncology of the Papageorgiou Hospital, a tertiary cancer center in northern Greece. We retrospectively reviewed patient medical records to obtain clinicopathologic characteristics, EGFR mutation status, and follow-up data. The primary end point was time to treatment failure.

resultsOf the 198 evaluable patients, 25 (12%) had EGFR mutations. All patients with EGFR mutations except one received treatment with an EGFR tyrosine kinase inhibitor. Median times to treatment failure for patients with EGFR-mutant and wild-type disease were 15.8 and 7.1 months, respectively (hazard ratio, 0.58; 95% CI, 0.35 to 0.95; P = .031). There was no difference in overall survival between the two groups ( P = .293). No deviation from treatment guidelines or discontinuation of treatment regimens occurred because of logistic reasons or drug shortages.

conclusionDespite restrictions in the reimbursement policy and accompanying controls in the use of high-cost medicines, the national program enabled treatment of patients with EGFR-mutant NSCLC according to established guidelines. Therefore, the clinical outcomes of such patients treated in Greece during the economic crisis were in accordance with international standards.

Indexed as

Economic RecessionAntineoplastic AgentsCarcinoma, Non-Small-Cell LungErbB ReceptorsGreeceHumansMedical OncologyMutationProtein Kinase InhibitorsAntineoplastic AgentsEGFR protein, humanErbB ReceptorsProtein Kinase Inhibitors

Identifiers

PMID30260753
PMCPMC6223495
OpenAlexW2893853908

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.